Gensulin M30 Mechanism of Action

Pharmacotherapeutic group: Gensulin 30/70. ATC code: A10A D01. Gensulin 30/70 is a premixed suspension of rapid and intermediate acting insulin.
Pharmacology: Pharmacodynamics:The prime activity of insulin is the regulation of glucose metabolism.
In addition insulin has several anabolic and anti-catabolic actions on a variety of different tissues. Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.
The typical activity profile (glucose utilisation curve) following subcutaneous injection is illustrated as follows by the heavy line. Variations that a patient may experience in timing and/or intensity of insulin activity are illustrated by the shaded area. Individual variability will depend on factors such as size of dose, site of injection temperature and physical activity of the patient. (See figure.)

Click on icon to see table/diagram/image

Pharmacokinetics: Insulin pharmacokinetics do not reflect metabolic activity of the hormone. Thus, while assessing insulin activity, it is more appropriate to analyse glucose utilisation curves (as previously explained).
Toxicology: Preclinical safety data: Gensulin M30 is human insulin produced by recombinant technology. No serious adverse events have been reported in subacute toxicity studies. In a series of in vitro and in vivo toxicity tests, Gensulin M30 was not mutagenic.